Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.
- Conditions
- Cardiac Procedure ComplicationIschemic Heart DiseaseValve Heart DiseaseDefect Septal
- Interventions
- Other: Off-pump CABGOther: On-pump CABGOther: Pump-assisted CABGOther: Valve Repair Procedure without CABG.Other: Valve Repair Procedure with CABG.
- Registration Number
- NCT03786965
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Brief Summary
The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.
- Detailed Description
To assess outcomes after cardiac surgery procedures. To investigate serum level of myeloperoxidase, morphology of left atrium appendage, to perform genetic analysis and cell biology.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2000
- ischemic heart disease with indications for operation
- valve disease with indications for operation
- ischemic heart disease combined with valve disease with indications for operation
- patient refusal
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Off-pump CABG. Off-pump CABG Off-pump CABG. On-pump CABG. On-pump CABG On-pump CABG. Pump-assisted CABG. Pump-assisted CABG Pump-assisted CABG. Heart Valve Procedure without CABG. Valve Repair Procedure without CABG. Heart Valve Procedure without CABG. Heart Valve Procedure with CABG. Valve Repair Procedure with CABG. Heart Valve Procedure with CABG.
- Primary Outcome Measures
Name Time Method Stroke. within 30 days after procedure. Stroke (MRI changes or corresponding neurologist record).
Infection or febrile. within 30 days after procedure. Infection or febrile (t\> 37 or CRP elevation or long regeneration of surgical wound).
Respiratory dysfunction. within 30 days after procedure. Respiratory dysfunction (pulmonary ventilation longer than 2 days).
Death within 30 days after procedure. within 30 days after procedure. Death within 30 days after surgical procedure.
Acute myocardial infarction. within 30 days after procedure. Acute myocardial infarction (ST-changes with troponin I \> 10 ng/ml).
Renal dysfunction. within 30 days after procedure. Renal dysfunction if serum creatinine greater than 25% of upper reference range.
Arrhythmia within 30 days after procedure. Any type of arrhythmia including AV-block.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Nikolai Bunenkov
🇷🇺Saint-Petersburg, Non-US/Non-Canadian, Russian Federation